bioAffinity Technologies Q2 CyPath Lung sales rise over 200% year-over-year

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) reported that sales volume of its CyPath® Lung diagnostic test grew more than 200% year-over-year in the second quarter of 2026, according to a company press release.

The number of tests sold in Q2 2026 also increased more than 30% compared with the first quarter of 2026. The company attributed the growth to higher utilization among existing clients and a 155% increase in the number of physician offices ordering the test compared with Q2 2025.

The company said it has performed nearly 3,000 CyPath® Lung tests since the product's commercial launch. The test is used across pulmonology practices, lung nodule clinics, academic and community medical centers, and Veterans Affairs facilities.

"Physicians who try CyPath® Lung appreciate its benefits and continue to use it," said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies. "Repeat utilization suggests the test is becoming part of routine clinical decision-making for patients with indeterminate pulmonary nodules."

CyPath® Lung is a noninvasive test that uses flow cytometry and artificial intelligence to analyze patient sputum samples. In a published clinical trial involving high-risk patients with small indeterminate lung nodules, the test reported 92% sensitivity, 87% specificity, 88% accuracy, and a 99% negative predictive value. It is marketed as a Laboratory Developed Test and is not intended as a sole diagnostic tool.

The company said it is conducting a large-scale longitudinal clinical study to generate additional validation data and is exploring use of the test to monitor lung cancer survivors after treatment. It also has an research and development pipeline that includes diagnostic tests for asthma and chronic obstructive pulmonary disease.

bioAffinity Technologies expects to report full financial results for Q2 2026 in August.

You May Also Be Interested In

• NVIDIA reports 9.3% passive stake in Nebius
• Steel Dynamics (STLD) Misses Q2 EPS by 7c
• Farmers & Merchants Bancorp (FMCB) Reports Q2 EPS of $36.39